Physiomics AACR Presentation

Physiomics PLC
13 February 2008

                                                                  Physiomics plc
                                                             The Magdalen Centre
                                                         The Oxford Science Park
                                                          Robert Robinson Avenue
                                                                          Oxford
                                                                         OX4 4GA
                                                                              UK

                                                                Tel [phone]
                                                                Fax [phone]

13 February 2008



                 Physiomics plc ('Physiomics' or 'the Company')

    Physiomics to present on Chronotherapy at the Annual Meeting of American
                    Association of Cancer Research ('AACR')

Physiomics plc (AIM: PYC), the Oxford, UK based  systems biology company, is
pleased to announce that it will be participating in the 2008 AACR Annual
Meeting, taking place in San Diego, on 12-16 April 2008.  Dr Eric Fernandez,
will present a development update on the Company's chronotherapy research
program, as part of the EU funded TEMPO (Temporal Genomics for Tailored
Chronotherapeutics) project. The abstract will be published in the 2008
Proceeding of the AACR and will be presented in the poster session 'Cellular and
Molecular Biology 8', scheduled for 1:00 pm on 13 April.



More information about the conference may be found at www.aacr.org



For further information:

 Physiomics plc                                          [phone]
 Dr Christophe Chassagnole, COO
 E-mail: [e-mail]
 Grant Thornton Corporate Finance                       [phone]
 Philip Secrett, Colin Aaronson
 


About TEMPO project (LSHG-CT-2006-037543)

In 2006 Physiomics has been selected to participate in the TEMPO Project as one
of four Industry partners working closely with four distinguished European
academic research groups. The project is coordinated by INSERM unit director
Prof Francis Levi, at Paul Brousse hospital in Villejuif (France).



This three year programme is exploring the effect of circadian rhythms (the
body's clock) on changes in cell proliferation and the effectiveness of cancer
drugs and will use this knowledge to optimise treatment.  The aim is to optimise
treatment of individual patients taking into account the 24h rhythms generated
by the patient's biological clock.  Physiomics is using its cell simulation
technologies to study the effect of cancer drugs on the cell cycle/circadian
clock system behaviour, at the cellular level, the cell population level
(virtual Fluorescence-Activated Cell-Sorting experiment) or tissue level
(virtual tumour). Using pharmacokinetics simulation in connection with
pharmacodynamics profile, Physiomics will help establish one or more
physiological relevant drug regimes and delivery schedules.



Physiomics will receive approximately £169,000 (€252,650) of matched funding
over the three year period and if successful will share in 3 to 5 new
therapeutic schedules according to the patient profiles for 2 main drug classes
against cancer and more specifically colorectal cancer. TEMPO develops tools
that will enable to select the best administration schedule for anti-cancer
drugs, taking into account the genes expression profile of the patient. Under
temporal control of the drug administration, the efficacy as well as the
toxicity will be controlled in an optimised manner.



For further information, please visit www.chrono-tempo.org



About Physiomics plc

Physiomics plc (AIM:PYC) is a computational systems biology services company
applying simulations of cell behaviour to drug development to reduce the high
attrition rates of clinical trials. As 80-90 per cent of all clinical drug
candidates fail to reach the market, estimates1 show that an overall ten per
cent improvement in success rates could reduce the cost of one drug's
development by as much as $242 million, from the current estimate of around $800
million.

Physiomics develops computational systems biology models to predict and
understand cancer drug efficacy from pre-clinical research to clinical
development. Physiomics has created detailed mathematical models incorporating
most important molecular events taking place during the human cell cycle and
apoptosis processes. Physiomics developed SystemCell(R) technology, a
multi-cellular environment software, which enables the simulation of population
of 'virtual cells'.

Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in
2004. For further information, please visit www.physiomics-plc.com



SystemCell(R) is a registered trademark of Physiomics plc

1Tufts Centre Impact Report 2002






                      This information is provided by RNS
            The company news service from the London Stock Exchange